Interestingly, it has proposed that since CD103+ CD8+ TIL frequently express PD-1 and Tim-3, and this T cell subset is much more highly susceptible to activation-induced cell death than CD103- T cell subset, targeting PD-1/PD-L1 signaling could enhance the anti-tumor activity of this population. The gene discussed is CD8A; the disease is neoplasm.